Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

Clicks: 246
ID: 6656
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #96 of 194 articles by views in journal of hepatocellular carcinoma

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy Ji Hye Jang, Jin-Woo Lee, Ji Taek Hong, Young-Joo Jin Division of Gastroenterology and Hepatology, Inha University School of Medicine and Hospital, Incheon, Republic of Korea Abstract: Transarterial chemoembolization (TACE) is the standard treatment for patients with Barcelona Clinic Liver Cancer-intermediate stage hepatocellular carcinoma (HCC). The concept of drug-eluting bead TACE builds on the rationale of intratumoral drug delivery, and drug-eluting bead TACE has been shown to provide consistent and reliable results and to significantly diminish systemic drug exposure, liver toxicity, and drug-related adverse events as compared with conventional TACE. Based on the belief that combinations of TACE and other local or systemic therapies have several theoretical advantages, many clinical trials have been conducted to evaluate the effectiveness of TACE in combination with local treatment such as radiofrequency ablation or radiotherapy, and systemic therapy such as sorafenib or another molecular therapy. TACE has also been used as a preoperative adjuvant chemotherapy in patients with HCC to improve survival and as a bridging therapy before liver transplantation to downstage HCC. In the present evidence-based review, the authors summarize the current status of these transcatheter arterial embolic therapies in HCC. Keywords: transarterial chemoembolization (TACE), hepatocellular carcinoma (HCC), evidence-based review
Reference Key
ji2015transarterialjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ji Hye Jang;Jin-Woo Lee;Ji Taek Hong;Young-Joo Jin and
Journal journal of hepatocellular carcinoma
Year 2015
DOI
10.2147/JHC.S44380
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.